Abstract
In the course of our ongoing program dedicated to the synthesis of anti-proliferative compounds, we prepared new troglitazone derivatives bearing a biphenyle moiety. The chromane heterocycle was further replaced by imidazole and triazole derivatives. Many compounds exhibited fair to high activity towards various cancer cell lines. Among them, compound 17b reduced cell viability leading to only 22-34% viable cells in four cancer cell lines at 10 µM, but unfortunately also led to a low (13%) cell viability of non-malignant primary cultured human hepatocytes at 200 µM. Interestingly, compound 11b also reduced cell viability in colon and liver cancer cell lines (29% and 24% cell viability respectively at 10 µM), but maintained a high cell viability of non-malignant hepatocytes (reaching 71% cell viability at 200 µM), thus exhibiting a huge selectivity.
Keywords: Cancer, Chromane, Hepatotoxicity, Imidazole, Thiazolidine-2, 4-dione, Triazole, Troglitazone.
Letters in Drug Design & Discovery
Title:Synthesis and Anti-Proliferative Activity of New Biphenyle-Benzylidenethiazolidine- 2,4-dione Bis-Adducts Containing Various Heterocyclic Cores
Volume: 11 Issue: 3
Author(s): Maxime Meyer, Sandra Kuntz, Isabelle Grillier-Vuissoz, Helene Martin, Lysiane Richert, Stephane Flament, Yves Chapleur and Michel Boisbrun
Affiliation:
Keywords: Cancer, Chromane, Hepatotoxicity, Imidazole, Thiazolidine-2, 4-dione, Triazole, Troglitazone.
Abstract: In the course of our ongoing program dedicated to the synthesis of anti-proliferative compounds, we prepared new troglitazone derivatives bearing a biphenyle moiety. The chromane heterocycle was further replaced by imidazole and triazole derivatives. Many compounds exhibited fair to high activity towards various cancer cell lines. Among them, compound 17b reduced cell viability leading to only 22-34% viable cells in four cancer cell lines at 10 µM, but unfortunately also led to a low (13%) cell viability of non-malignant primary cultured human hepatocytes at 200 µM. Interestingly, compound 11b also reduced cell viability in colon and liver cancer cell lines (29% and 24% cell viability respectively at 10 µM), but maintained a high cell viability of non-malignant hepatocytes (reaching 71% cell viability at 200 µM), thus exhibiting a huge selectivity.
Export Options
About this article
Cite this article as:
Meyer Maxime, Kuntz Sandra, Grillier-Vuissoz Isabelle, Martin Helene, Richert Lysiane, Flament Stephane, Chapleur Yves and Boisbrun Michel, Synthesis and Anti-Proliferative Activity of New Biphenyle-Benzylidenethiazolidine- 2,4-dione Bis-Adducts Containing Various Heterocyclic Cores, Letters in Drug Design & Discovery 2014; 11 (3) . https://dx.doi.org/10.2174/15701808113106660080
DOI https://dx.doi.org/10.2174/15701808113106660080 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antineoplastic Potential of Medicinal Plants
Recent Patents on Biotechnology Targeting the Epidermal Growth Factor Receptor in Glioblastoma Treatment
Current Signal Transduction Therapy Cancer/Testis Antigens Trigger Epithelial-Mesenchymal Transition and Genesis of Cancer Stem-Like Cells
Current Pharmaceutical Design Induced Pluripotent Stem Cells (iPSCs) in the Modeling of Hepatitis C Virus Infection
Current Stem Cell Research & Therapy Novel Approaches for RNA Interference and their Application in Cancer Therapy
Current Pharmacogenomics Sources of β-Cells for Cell Therapy in Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Changing Face of HIV/AIDS in Treated Patients
Current HIV Research Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Role of Natural Phenolic Compounds in Cancer Chemoprevention via Regulation of the Cell Cycle
Current Pharmaceutical Biotechnology Approaches to Target Profiling of Natural Products
Current Medicinal Chemistry Epigenetic Regulation of Epithelial to Mesenchymal Transition
Current Cancer Drug Targets Fisetin Attenuates AKT Associated Growth Promoting Events in AflatoxinB1 Induced Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Neutrophil MiRNA-128-3p is Decreased During Active Phase of Granulomatosis with Polyangiitis
Current Genomics Synthetic Peptides in the Diagnosis of HIV Infection
Current Protein & Peptide Science Of Man in Mouse: Modelling Human Cancer Genotype-Phenotype Correlations in Mice
Current Genomics Reduction in Ischemic Cerebral Infarction is Mediated through Golgi Phosphoprotein 3 and Akt/mTOR Signaling Following Salvianolate Administration
Current Neurovascular Research Delivery Methods of Camptothecin and Its Hydrosoluble Analogue Irinotecan for Treatment of Colorectal Cancer
Current Drug Delivery Cytoplasmic CXCR4 High-Expression Exhibits Distinct Poor Clinicopathological Characteristics and Predicts Poor Prognosis in Triple-Negative Breast Cancer
Current Molecular Medicine The Role of Essential Oils and the Biological Detoxification in the Prevention of Aflatoxin Borne Diseases
Current Topics in Medicinal Chemistry Pharmacologic Evidence of Green Tea in Targeting Tyrosine Kinases
Current Reviews in Clinical and Experimental Pharmacology